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Abstract
Background
While there has been a rapid global scale-up of antiretroviral therapy programs over the
past decade, there are limited data on long-term outcomes from large cohorts in resource-
constrained settings. Our objective in this evaluation was to measure multiple outcomes
during first-line antiretroviral therapy in a large treatment program in Nigeria.
Methods
We conducted a retrospective multi-site program evaluation of adult patients (age15
years) initiating antiretroviral therapy between June 2004 and February 2012 in Nigeria.
The baseline characteristics of patients were described and longitudinal analyses using pri-
mary endpoints of immunologic recovery, virologic rebound, treatment failure and long-
term adherence patterns were conducted.
Results
Of 70,002 patients, 65.2% were female and median age was 35 (IQR: 29–41) years; 54.7%
were started on a zidovudine-containing and 40% on a tenofovir-containing first-line regi-
men. Median CD4+ cell counts for the cohort started at 149 cells/mm3 (IQR: 78–220) and
increased over duration of ART. Of the 70,002 patients, 1.8% were reported as having
died, 30.1% were lost to follow-up, and 0.1% withdrew from treatment. Overall, of those
patients retained and with viral load data, 85.4% achieved viral suppression, with 69.3%
achieving suppression by month 6. Of 30,792 patients evaluated for virologic failure, 24.4%
met criteria for failure and of 45,130 evaluated for immunologic failure, 34.0% met criteria
for immunologic failure, with immunologic criteria poorly predicting virologic failure. In
adjusted analyses, older age, ART regimen, lower CD4+ cell count, higher viral load, and
inadequate adherence were all predictors of virologic failure. Predictors of immunologic
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failure differed slightly, with age no longer predictive, but female sex as protective; addition-
ally, higher baseline CD4+ cell count was also predictive of failure. Evaluation of long-term
adherence patterns revealed that the majority of patients retained through 84 months main-
tained95% adherence.
Conclusion
While improved access to HIV care and treatment remains a challenge in Nigeria, our study
shows that a high quality of care was achieved as evidenced by strong long-term clinical,
immunologic and virologic outcomes.
Introduction
The rapid scale-up of global HIV antiretroviral therapy (ART) in resource-constrained settings
(RCS) over the past decade has successfully enrolledmillions of HIV-infected patients in care
and treatment programs [1]. While the initial goal of these programs was to initiate large num-
bers of patients on ART and, subsequently, reduce overall morbidity and mortality, the con-
tinuing aim is to maintain patients on high quality life-long care. Many studies have examined
short- and medium-termoutcomes in adult patients enrolled in ART programs across the
globe, but there are relatively limited data on the long-term outcomes for large-scale ART pro-
grams [2–12].
Nigeria is the most populous country in sub-Saharan Africa with an estimated population
of nearly 180 million and current estimated HIV prevalence of 3.2%. Despite a low HIV preva-
lence, Nigeria has the second highest burden of HIV infection in the world [1,13,14]. In 2014,
it was estimated that about 3.4 million people were living with HIV, with approximately
230,000 newHIV infections, representing almost 10% of the global HIV pandemic [13,15].
In 2001, the Federal Government of Nigeria initiated a national ART program as part of its
enhanced response for the care and support for HIV-infected persons [16]. The Nigerian
National ART program was initially rolled out to 25 designated ART centers distributed across
the country’s six geopolitical zones. In collaboration with the Nigerian National ART Program,
which had initiated treatment for over 13,000 HIV patients by mid-2004, the Harvard T. H.
Chan School of Public Health (Harvard Chan) and Nigerian collaborators at the AIDS Preven-
tion Initiative in Nigeria (APIN) initiated a rapid scale-up of HIV care and treatment programs
through support from a PEPFAR grant beginning in 2004. The significant contribution of the
PEPFAR program to the national ART program is apparent in the nearly exponential increase
in patients initiated on ART between 2004 and 2012, with PEPFAR providing over 50% of the
funding support for the scale-up. Over that same time period, national HIV prevalence esti-
mates decreased from 3.8% [3.4%-4.1%] in 2005 to 3.2% [3.0%-3.5%] in 2013 [1]. From 2009
to 2012, the number of patients on ART in Nigeria rose from 303,000 to 491,000, and contin-
ued to increase to over 747,000 in 2014 [13].
Between 2004–2012, the Harvard/APIN PEPFAR program expanded from 6 to 36 hospitals
and clinics, including 9 tertiary referral hospitals, 23 secondary hospitals or primary health
clinics, and four non-governmental organizations (NGOs) in 9 of the 36 states of Nigeria
(Benue, Borno, Enugu, Kaduna, Lagos, Ogun, Oyo, Plateau, and Yobe). Standardized protocols
were developed for clinical management, laboratory testing and pharmacy handling, conform-
ing to an optimized standard of care consistent with Nigerian National ART and PMTCT
guidelines. Expanded and renovated clinics, pharmacies and equipped laboratories allowed for
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the provision of ART to large numbers of patients [17]. Computerized data entry of patients’
clinical, laboratory and pharmacy records was developed and implemented, making it possible
to monitor the progress at the sites electronically [18]. As of March 2012, approximately
100,000 adult patients had received ART and 160,000 had received some form of HIV-related
care. In addition, nearly 400,000 women had been provided prevention of mother-to-child
transmission (PMTCT) services,with 20,000 mothers and children receiving the intervention.
In this evaluation, we provide data on long-term outcomes of adult patients enrolled in the
Harvard/APIN PEPFAR Program between 2004–2012. A main objective of the study was to
describe the baseline characteristics of the adult patients treated in the Harvard/APIN PEPFAR
program and any changes in baseline characteristics over the 8-year study period. The other
major objective of the study was to assess the long-term outcomes of ART, including immuno-
logic and virologic. Additionally, we examined long-term adherence patterns for patients
retained on ART.
Methods
Patient Information
The Harvard/APIN PEPFAR adult ART program enrolled patients with documented evidence
of HIV infection by rapid test screening and HIV immunoblot confirmation. Since the Govern-
ment of Nigeria commenced their ART program in 2002, the cohort included patients that
might have already had as much as 2 years of previous ART at the time that they were enrolled
in the Harvard/APIN PEPFAR program. For ARV-naïve patients, eligibility for ART in the
Harvard/APIN PEPFAR program followed the Nigerian National Guidelines [19,20], which
closely followed theWorld Health Organization (WHO) Guidelines at the time of patient
enrollment [21–23]. Starting in 2004, patients were considered eligible for ART if their CD4+
cell counts dropped below 200 cells/mm3 or if symptomatic with CD4+ cell counts below 350
cells/mm3; criteria shifted to include CD4+ cell counts below 350 cells/mm3 regardless of
symptoms starting in 2010. Written informed consent was obtained from all patients upon ini-
tial enrollment; for minors under 18 years of age, written informed consent from the parent/
legal guardian and written assent to participate from the minor were dually documented. The
protocol and consent forms were reviewed and approved by the Harvard Chan Institutional
ReviewBoard (IRB) and the Nigerian Institute for Medical Research IRB, which is a Federal-
wide Assurance (FWA)-approved IRB that covers all other Harvard/APIN PEPFAR program
sites.
We conducted a retrospective evaluation of the prospectively collected data for patients who
were provided routine ART services through the Harvard/APIN PEPFAR Program and con-
sented to participation in future evaluations. The analyses on long-term outcomes included
patients who were enrolled on ART between June 2004-February 2012. All patients were at
least 15 years of age at enrollment. Patients who had HIV-2 or dual HIV-1/2 infections, or
were on a non-standard first-line (1L) ART regimen (i.e, not containing two nucleoside reverse
transcriptase inhibitors [NRTI] plus one non-nucleoside reverse transcriptase inhibitor
[NNRTI]) were excluded from the long-term outcomes analyses. Additionally, some issues in
early viral load (VL) testing procedures and pharmacy documentation issues at two of our sites
were discovered; therefore, patients who enrolled at either of those two sites before April 2007
were excluded from the evaluations as some of their early data were not reliable.
Treatment
In early 2000, the production of generic ART drugs was just beginning and formed the basis of
many ART programs in developing countries, including Nigeria. At PEPFAR program
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initiation in Nigeria, the most common 1L ART included stavudine (d4T), lamivudine (3TC),
and nevirapine (NVP). In late 2006, the increased recognition of the toxicity and inferior effi-
cacy of regimens containing d4T prompted the revision of international guidelines, with even-
tual removal of d4T from recommended 1L regimens. In 2003–2005, access to tenofovir
(TDF)-based regimens was spreading to RCS, although the cost of the branded version slowed
its introduction. In 2008–2009, the introduction of the generic equivalents and the fixed-dose
combination (FDC) Atripla, which was a combination of TDF, emtricitabine (FTC), and efa-
virenz (EFV), expanded usage of TDF. In the Harvard/APIN PEPFAR program, TDF-based
regimens were considered for patients with hepatitis B virus (HBV) co-infection and those
with anemia; NVP was the NNRTI of choice in women of child bearing potential, due to the
teratogenic potential of EFV; and, in cases of TB-HIV co-infection, patients were switched to
EFV at higher dosing of 600 or 800 mg/day.
Laboratory Measurements
Patient samples were drawn for laboratory testing at baseline, 6 months post-initiation of ART
and every 6 months thereafter, regardless of prior treatment status. Laboratory tests included auto-
mated hematology, clinical chemistries, CD4+ cell counts by flow cytometry (CyFlow1, Partec,
Munster, Germany), and plasma VLs using the COBAS1 Amplicor version 1.5 (RocheDiagnos-
tics, Rotkreuz, Switzerland). Hematology consisted of a complete blood count and clinical chemis-
tries. Additional chemistry evaluations could be requested based on the physician’s discretion.
Serology for HBV (Monolisa HBsAg Ultra3; Bio-Rad,Hercules, CA, USA) and hepatitis C virus
(HCV) (Dia.Pro Diagnostic Bioprobes srl, Milan, Italy) infectionswas conducted at baseline. All
patients were evaluated for tuberculosis (TB) using sputum and/or chest radiograph at baseline
and at all subsequent clinical visits if suspected clinically [24]. Patients were switched to 2L regi-
mens either based on virologic or clinical criteria, per Nigerian National Guidelines [19,20].
Data Management
From the start of the Harvard/APIN PEPFAR program, all patient demographic, clinical and
laboratory data were electronically captured using a Harvard Chan School-designedFileMaker
Pro (FileMaker Pro, Santa Clara, CA) electronicmedical record system (EMRS) [18]. Data
forms were checked for errors prior to entry by data entry staff and entered into the EMRS,
which had built-in error checks, including checks for laboratory values that were outside the
ranges of acceptable values and flags for missing values. Data entry staff checked their records
daily and then transferred files to data managers for weekly checks. Additional information
regarding the structure of the EMRS were previously presented by Chaplin et al [18].
Definitions
We evaluated baseline demographic (age, sex, education, employment status, marital status,
HIV transmission risk category, enrollment year and enrollment site type) and clinical (ART
regimen,WHO clinical stage, TB co-infection,HBV and/or HCV co-infection, bodymass
index (BMI), CD4+ cell count, VL and anemia) factors, where baseline was defined as the time
of ART initiation. Baseline clinical assessments or laboratory evaluations for naïve patients
were the closest measurements to, and up to six months before or 0.5 month after, their first
ART pick-up date.
For analyses, age was converted to a categorical variable based on quartiles and occupation
was collapsed into non-income generating (i.e., unemployed, students, job applicants, house-
wives/homemakers, and retirees) and income generating (laborers, service, and administrative
support professionals vs. manager and other professional) categories. Clinical variables were
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collapsed into categories based on relevant thresholds for the regression. BMI was grouped into
threeWHO-defined categories: underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), over-
weight (25.0). Anemia was defined usingWHO-recommended hemoglobin cut-offs: non-
anemia (12 g/dL for women and13 g/dL for men), mild/moderate anemia (8–11.9 g/dL for
women and 8–12.9 g/dL for men), and severe anemia (<8 g/dL; pregnancy was not differenti-
ated). VL at baseline was stratified into three categories (10,000 copies/mL, 10,001–100,000
cp/mL, and>100,000 cp/mL). Virologic suppression was defined as a single viral load that was
below the limit of detection (400 copies/mL). Using pharmacy prescription electronic refill
records, which have been shown to be a valid proxy [25,26], average percent ART adherence
was calculated as number of days supplied over total days in the given time interval, adjusting
for leftover medication. Adherence categories were based on previously published conventions:
95%, 80–94.9%, and<80% [11,27–30].
Patients were classified as lost to follow-up (LTFU) if they had missed the last scheduled
appointment by more than two months by the time of database closure. Patients for whom
death, withdrawal, or transfer to non-Harvard/APIN sites was recorded during the period of
evaluation were not considered LTFU. Data on deaths, withdrawals, or transfers were passively
obtained when either patients or their acquaintances provided the information; active tracing
of patients that were late to appointments was not feasible as part of the program.
Virologic failure (VF) was evaluated only for patients on ART5.5 months (to provide win-
dow of time to include VLs close to month 6) and with2 VLs after 6 months, and was defined
as two consecutive VLs after 6 months on ART, which surpassed 1,000 copies/mL. Immuno-
logic failure (IF) was evaluated for patients on ART 5.5 months and with1 CD4+ cell count
after 6 months and was defined using the following criteria: 1) CD4+ count<100 cells/mm3
after 6 months of treatment; 2) CD4+ count below baseline level after 6 months of treatment;
and/or, 3) CD4+ count less than 50% of peak on treatment level. Patients that were switched to
2L ART were also considered virologic and immunologic failures. Patients for whom an alter-
nate 1L regimen was substituted due to toxicity, stock-outs of certainmedications, or other
related issues were still considered to be on 1L and were not included in the failure categories.
Statistical Analysis
Baseline demographics and clinical characteristics were measured using standard descriptive
statistical methods. Bivariate comparisons of categorical variables were performed using the Χ2
test. A non-parametric test for trend was utilized for examining patterns in baseline CD4+ cell
counts by enrollment year. Statistical significancewas defined at an α-level of 0.05.
Kaplan-Meier survival analyses were used to estimate the time from the initiation of ART to
two different major outcomes: 1) virologic failure; and, 2) immunologic failure. For patients
who did not reach the endpoint, the data were censored at the date of the last visit. The log-
rank test was used to compare survival times between strata for categorical variables. All pre-
dictors that were significant at the p<0.20 level in bivariate methods were further evaluated in
a random effects Cox proportional hazards model, which accounted for heterogeneity between
sites and was fitted using backward elimination. Additionally, we incorporated time-dependent
factors into the analyses, including BMI, CD4+ cell count, VL, anemia status, and average per-
cent adherence, which were measured every six months. VF during a given time periodwas
assessed for associations with time-dependent factors measured during the previous time
period. Since VF is defined as occurring at the first of two consecutive VLs>1000 cp/mL, any
recorded VL during the time period immediately preceding VF would generally be suppressed;
therefore, in the VF analysis only, we assessed unsuppressed VL during the current time period
as a time-dependent predictor of VF, i.e., of a second consecutive unsuppressed VL. To address
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potential bias due to patients who were excluded because of missing data, multiple imputation
of missing values was performed, following exploration of pattern of missigness and verifica-
tion that data were missing at random, using chained equations assuming missing at random
and 10 imputed data sets. Values for the Cox models were generated using both complete cases
and multiply imputed data.
All statistical analyses were conducted using Stata version 13.1 (Stata Corporation, College
Station, Texas, USA).
Results
Overview
From June 2004 through February 2012, 99,887 adult patients were enrolled in the Harvard/
APIN PEPFAR Program; of those patients, 91,083 were mono-infectedwith HIV-1 and had
reliably collected data in the program EMRS.Within that subset, 86,471 initiated standard 1L
regimens with 70,002 (81.0%) of those patients ARV-naïve and 16,469 (19.0%) with previous
ARV experience at initiation in the Harvard/APIN PEPFAR program (Fig 1). The median fol-
low-up period for all HIV-1-infected patients initiated on standard 1L regimens was 21.3
months (interquartile range; IQR: 5.2–41.3), with a range of 0–91.9 months. The median for
those that were ARV-naïve at enrollment was 17.9 months (IQR: 4.0–38.3; range 0–87.8) and
36.0 months (IQR: 15.5–49.8) for those that were ARV-experienced.
ARV-Naïve Patients
Collectively, these 70,002 patients represent 136,852 (95% CI: 135,909–137,794) person-years
(PY) on ART. Amongst the ARV-naïve patients enrolled on one of the standard 1L regimens,
the majority were women (65.2%). The median age at entry was 35 years (IQR: 29–41), and
was higher for males, at 39 years (IQR: 33–45), than for females, at 32 years (IQR: 27–38;
p<0.0001; Fig 2).
The largest proportion of patients were initiated on AZT+3TC+NVP (46.1%; Table 1), but
the proportions of patients initiating ART on the 6 standard 1L regimens changed significantly
over the years of observation (Fig 3). The only regimen prescribed in 2004 was d4T+3TC+
NVP, but that regimen was eventually phased out after AZT- and TDF-containing regimens
were introduced in 2005. There was a large shift to AZT-containing regimens in 2006 and grad-
ual shift to a more equal balance betweenAZT- and TDF-containing regimens by 2010.
The median follow-up for patients who started on the different regimens were as follows:
31.7 months (IQR: 2.9–57.9; range: 0–79.8) for d4T+3TC+EFV; 50.6 (IQR: 14.7–77.0; range:
0–87.8) for d4T+3TC+NVP; 24.0 months (IQR: 4.6–43.9; range: 0–80.0) for AZT+3TC+EFV;
19.3 months (IQR: 4.8–38.7; range: 0–81.0) for AZT+3TC+NVP; 12.0 months (IQR: 2.3–29.2;
range: 0–77.5) for TDF+3TC/FTC+EFV; and, 16.3 months (IQR: 3.7–35.6; range: 0–77.7) for
TDF+3TC/FTC+NVP (p = 0.001; Fig 4).
Baseline Clinical Characteristics
Of the 70,002 ARV-naïve patients, 59,096 (84.4%) had a documentedWHO Stage at ART initi-
ation, of which more than half were asymptomatic or relatively free of symptoms (32,230;
54.5%) meeting theWHO Stage I or II definition. Amongst the naïve patients, 10.2% were
HBV-positive, 3.6% had documentation of HCV, 8.9% had evidence of severe anemia, and
20.4% had TB at time of ART initiation. Laboratorymeasurements indicated that the median
baseline CD4+ cell count was 149 cells/mm3 (IQR: 78–220) and the median baseline HIV RNA
load was 71,310 copies/mL (IQR: 13,293–260,000). Evaluation of baseline CD4+ cell count and
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Fig 1. Flowchart highlighting enrolled patient population.
doi:10.1371/journal.pone.0164030.g001
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WHO stage by enrollment year revealed an overall increasing trend in median baseline CD4+
cell counts between 2004–2012 (ptrend<0.001; Fig 5A) and trend of increasing percentage of
patients who initiated ART withWHO clinical stage 1 or 2 between 2008–2012, respectively
(p<0.0001; Fig 5B). Of the ART-naïve patients, 1,231 (1.8%) patients were reported as having
died, 21,096 (30.1%) were lost to follow-up, and 96 (0.1%) withdrew from therapy. The major-
ity of patients lost to follow-up were lost within 6 months of ART initiation; of the total 70,002
ART-naïve patients enrolled during the study period, 17.7% were lost by month 6, 21.5% by
month 12, 25.9% by month 24, 28.2% by month 36, 29.3% by month 48, 29.8% by month 60,
30.1% by month 72, and 30.1% by month 84.
Immune Recovery
Median CD4+ cell count for the cohort increased continually over duration on ART from 149
cells/mm3 (IQR: 78 – 220) at ART initiation to 487 cells/mm3 (IQR: 343–666) at 72 months,
after which it appeared to plateau (Fig 6A). The greatest gain was from 0 to 6 months when the
median CD4+ cell count gain was 130 cells/mm3 (IQR: 57 – 223, n = 35,292); the value differed
by baseline CD4+ cell count: 120 cells/mm3 (IQR: 63–196) for patients with a baseline CD4+
Fig 2. Median age at ART initiation by sex, ARV-naïve patients (N = 70,002).
doi:10.1371/journal.pone.0164030.g002
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Table 1. Baseline demographic and clinical characteristics.
All Patients ARV-naïve* ARV-experienced*
Characteristic n = 86,471 n = 70,002 n = 16,469
Time on ART**
Range, months 0–91.9 0–87.8 0–91.9
Median, months (IQR) 21.3 (5.2–41.3) 17.9 (4.0–38.3) 36.0 (15.5–49.8)
Age, years
15–29 22,125 (25.6) 18,855 (26.9) 3,270 (19.9)
30–34 18,394 (22.4) 15,830 (22.6) 3,564 (21.6)
35–40 20,323 (23.5) 16,249 (23.2) 4,074 (24.7)
41 24,549 (28.4) 18,982 (27.1) 5,547 (33.7)
Median (IQR) 35 (29–42) 35 (29–41) 36 (31–43)
Female Sex 56,386 (65.2) 45,605 (65.2) 10,781 (65.5)
Education
None 15,307 (17.7) 12,993 (18.6) 2,314 (14.1)
Primary 18,057 (20.9) 15,225 (21.8) 2,832 (17.2)
Secondary 29,298 (33.9) 24,428 (34.9) 4,870 (29.6)
Tertiary 21,159 (24.5) 16,054 (22.9) 5,105 (31.0)
Employment Status
Non-income-generating 20,248 (23.4) 16,509 (23.6) 3,739 (22.7)
Laborers, service, administrators 58,955 (68.2) 48,193 (68.9) 10,762 (65.3)
Professional, managerial 5,673 (6.6) 4,141 (5.9) 1,532 (9.3)
Marital Status
Single 16,340 (18.9) 13,494 (19.3) 2,846 (17.3)
Married 49,063 (56.7) 40,038 (57.2) 9,025 (54.8)
Divorced/Separated 7,419 (8.6) 6,233 (8.9) 1,186 (7.2)
Widowed 12,425 (14.4) 9,334 (13.3) 3,091 (18.8)
Heterosexual Sex as Risk Factor 76,105 (88.0) 61,879 (88.4) 14,226 (86.4)
ART Enrollment Year
2004–2006 12,834 (14.8) 9,272 (13.3) 3,562 (21.6)
2007–2009 43,645 (50.5) 33,677 (48.1) 9,968 (60.5)
2010–2012 29,922 (34.7) 27,053 (38.6) 2,939 (17.9)
Tertiary Site 74,207 (85.8) 58,676 (83.8) 15,531 (94.3)
First-Line ART Regimen
TDF-3TC/FTC-EFV 14,755 (5.4) 13,865 (19.8) 890 (5.4)
TDF-3TC/FTC-NVP 15,296 (17.7) 14,160 (20.2) 1,136 (6.9)
AZT-3TC-EFV 6,809 (7.9) 6,043 (8.6) 766 (4.7)
AZT-3TC-NVP 38,561 (44.6) 32,297 (46.1) 6,264 (38.0)
d4T-3TC-EFV 440 (0.5) 286 (0.4) 154 (0.9)
d4T-3TC-NVP 10,610 (12.3) 3,351 (4.8) 7,259 (44.1)
WHO Stage at baseline
1 19,772 (22.9) 15,164 (21.7) 4,076 (24.7)
2 21,705 (25.1) 17,066 (24.4) 3,744 (22.7)
3 23,055 (26.7) 19,086 (27.3) 3,315 (20.1)
4 8,830 (10.2) 7,780 (11.1) 759 (4.6)
TB at baseline 16,764 (19.4) 14,253 (20.4) 2,511 (15.2)
HBV Status at baseline 8,696 (10.1) 7,157 (10.2) 1,539 (9.3)
HCV Status at baseline 3,058 (3.5) 2,531 (3.6) 527 (3.2)
BMI at baseline, kg/m2
(Continued)
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cell count100 cells/mm3 as compared to 140 cells/mm3 (IQR: 59–240) for those with baseline
101–200 cells/mm3 and (p<0.0001; Table 2). The median change in CD4+ cell count was low-
est in those with the highest baseline CD4+ cell count.
Table 1. (Continued)
All Patients ARV-naïve* ARV-experienced*
Characteristic n = 86,471 n = 70,002 n = 16,469
Underweight (<18.50) 11,371 (13.2) 10,283 (14.7) 1,088 (6.6)
Normal (18.50–24.99) 37,357 (43.2) 29,702 (42.4) 7,655 (46.5)
Overweight (25.00–29.99) 10,900 (12.6) 7,390 (10.6) 3,510 (21.3)
Obese (30.00) 3,351 (3.9) 2,177 (3.1) 1,174 (7.1)
Severe anemia at baseline 6,771 (7.8) 6,238 (8.9) 533 (3.2)
CD4 count at baseline, cells/mm3
100 23,176 (26.8) 21,516 (30.7) 1,660 (10.1)
101–200 26,378 (30.5) 23,863 (34.1) 2,515 (15.3)
201–350 21,232 (24.6) 17,249 (24.6) 3,983 (24.2)
>350 6,419 (10.7) 3,059 (4.4) 6,207 (37.7)
Median (IQR) 166 (88–254) 149 (78–220) 312 (182–491)
Viral load at baseline, copies/mL
10,000 21,489 (24.9) 12,260 (17.5) 9,229 (56.0)
10,001–100,000 20,924 (24.2) 18,955 (27.1) 1,969 (12.0)
>100,000 25,527 (29.5) 24,180 (34.5) 1,347 (8.2)
Median 45,730 (200–260,000) 71,310 (13,293–260,000) 486 (200–12,037)
* Values shown are n and % unless otherwise indicated; % account for missing data
**Time on ART in the Harvard/APIN PEPFAR Program; does not account for time ART prior to entry for those with previous ARV experience and/or time on
ART in another program for those that have transferred; value of 0 in the range refers to patients that made only 1 pharmacy visit and did not return,
therefore no months of follow-up.
doi:10.1371/journal.pone.0164030.t001
Fig 3. First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).
doi:10.1371/journal.pone.0164030.g003
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Virologic Suppression & Rebound
Among the patients that were retained beyond 6 months (n = 49,114) and had VL measured at
month 6 post-initiation (n = 29,298; 58.9%), 69.3% (n = 20,303) were considered to have
achieved early viral suppression (i.e., suppression by month 6). Of the patients that failed to
achieve early viral suppression, an additional 14,233 of the patients with subsequent VL data
eventually suppressed VL, resulting in an overall 85.4% (n = 34,536/40,418) that achieved viral
suppression ever. Using a longitudinal view, suppression rates for the study population gradu-
ally increased to 75.0% at 42 months and appeared to plateau through to month 84 (Fig 6B).
Using a viral rebound definition of two VLs>400 copies/mL or one VL>5,000 copies/mL, of
the patients that achieved early viral suppression, 21.0% (n = 4,262) experienced a viral
rebound. Of the patients that experienced the viral rebound following early viral suppression,
60.3% (n = 2,570) re-suppressed.
We also examined the association between baseline CD4+ cell counts and viral suppres-
sion at month 6 and month 12 post-initiation of ART. We found that of the patients initiat-
ing ART with CD4+ cell counts100 cells/mm3, 65.4% were suppressed at month 6 and
Fig 4. Median follow-up time on ART by first-line ART regimen, ARV-naïve patients (N = 70,002).
doi:10.1371/journal.pone.0164030.g004
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Fig 5. Baseline patient status by enrollment year, ARV-naïve patients. A) median baseline CD4+cell count (cell/mm3); and, B)
percentage patients by WHO clinical stage.
doi:10.1371/journal.pone.0164030.g005
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Fig 6. Clinical and virologic outcomes over duration on ART, ARV-naïve patients. A) median CD4+ cell count (cells/mm3) over time on
ART; and, B) percentage of patients with virologic suppression (400 copies/mL) over time on ART.
doi:10.1371/journal.pone.0164030.g006
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72.3% by month 12. Comparatively, for those starting at 101–200 cells/mm3, 70.7% were sup-
pressed by month 6 and 77.0% by month 12, and for those starting at 201–350 cells/mm3,
73.3% were suppressed at month 6 and 79.3% by month 12. Interestingly, after CD4+ cell
counts of 350 cells/mm3, we saw a declining trend as the baseline CD4+ cell counts increased,
where of those with 351–500 cells/mm3, 71.5% were suppressed at month 6 and 78.5% by
month 12 and of those with>500 cells/mm3 at baseline, only 64.6% were suppressed at
month 6 and 73.0% by month 12 (Table 2).
Treatment Failure by Immunologic & Virologic Criteria
In total, of 30,792 patients eligible to be assessed for VF, 7,504 (24.4%) patients met criteria for
failure resulting in an overall VF rate of 96.5 cases per 1000 PY (IQR, 94.3–98.7). The median
time to VF was 11.6 months (IQR: 7.6–19.8) and rate of VF was highest at month 6 at 306.0
cases per 1000 PY (IQR, 294.5–318.0), then decreased to 30.9 cases per 1000 PY (IQR, 26.5–
35.9) at month 42 at which point it appeared to plateau (Fig 7A). Of the 45,130 total patients
eligible to be assessed for IF, 15,353 (34.0%) met criteria for failure, resulting in an overall IF
rate of 182.1 cases per 1000 PY (IQR: 179.2 – 185.0). The median time to recorded IF was 16.0
months (IQR: 8.8–28.7) and rates were also highest at month 6 at 327.5 cases per 1000 PY
(IQR, 317.4–337.9) but plateaued early at month 18, after which it hovered between 130 to 152
cases per 1000 PY frommonth 24 to month 60. Over 50% of all failures occurredwithin the
first 12 months of ART for VF, and within the first 18 months of ART for IF. In assessing the
predictive power of immunologic criteria for detecting failure as compared to virologic criteria,
we found a 60.9% sensitivity, 69.9% specificity, 37.1% positive predictive value, and 86.0% neg-
ative predictive value. No notable trend was seen in percentage of patients with VF within the
first 18 months by enrollment year (Fig 7B).
In bivariate analyses, age, education, employment status, marital status, ART regimen, ART
enrollment year, site type,WHO stage, BMI, CD4+ cell count, HBV and HCV status, VL, ane-
mic state, adherence were all found to be predictors of VF (Table 3). Following multivariate
adjustments, factors that remained associated with VF in the model with multiple imputations
were age, ART regimen, CD4+ cell count, VL, and adherence. Baseline BMI and ART enroll-
ment year were of borderline significance in the complete case model, but the variables were no
longer significant following imputation. In the final model, the risk for VF was greater for
patients who were younger, on regimens other than TDF+EFV, had lower CD4+ cell counts
(both baseline and at prior visit), higher baseline VL, unsuppressed VL at current visit, and
lower percent ART adherence during the period preceding the visit. Our data indicate that for
this cohort, those on NVP regimens generally were at higher risk for VF than those on equiva-
lent EFV regimens. Patients on TDF+FTC/3TC+NVP, AZT+3TC+EFV, AZT+3TC+NVP, or
Table 2. Immunologic, virologic and adherence patterns by baseline CD4+ cell count, previously ARV-naïve patients (N = 70,002).
Baseline CD4+ Cell Count, cells/mm3 p-value
Outcome/pattern evaluated 100 101–200 201–350 351–500 >500
CD4+ cell count change by month 6, cells/mm3 (IQR) 120 140 140 <0.0001
(63–196) (66–234) (47–251)
% with viral suppression* by month 6 65.4 70.7 73.3 71.4 64.4 <0.001
% with viral suppression* by month 12 72.3 77.0 79.3 78.4 73.1 <0.001
% with average adherence95% at month 6 63.1 62.9 64.2 56.5 52.5 <0.001
% with average adherence <50% at month 6 6.4 6.5 6.3 11.7 14.3 <0.001
*Viral suppression defined as VL400 cp/mL
doi:10.1371/journal.pone.0164030.t002
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Fig 7. Characterization of treatment failure over time. A) Virologic and immunologic failure rates over duration on ART, 95% CI; and, B) Percentage of
patients with virologic failure within first 18 months on ART by enrollment year.
doi:10.1371/journal.pone.0164030.g007
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Table 3. Predictors of virologic and immunologic failure for ARV-naïve patients.
Predictors Virologic Failure Immunologic Failure
Bivariate
Analysis
Complete Multiple
Imputations**
Bivariate
Analysis
Complete Multiple
Imputations**Cases** Cases**
(n = 30,792) (n = 19,454) (n = 30,792) (n = 45,130) (n = 35,836) (n = 45,130)
HR (95% CI) aHR (95% CI) aHR (95% CI) HR (95% CI) aHR (95% CI) aHR (95% CI)
Age (vs. 15–29 yrs)
30–34 years 0.80 (0.72–0.88) 0.87 (0.81–0.94) 0.86 (0.81–0.92) 0.90 (0.87–0.94)
35–40 years 0.75 (0.70–0.81) 0.87 (0.82–0.93) 0.84 (0.79–0.89) 0.93 (0.88–0.98)
41+ years 0.67 (0.60–0.74) 0.79 (0.72–0.86) 0.78 (0.73–0.84) 0.88 (0.83–0.94)
Sex (Female vs. Male) 1.00 (0.96–1.04) 0.90 (0.88–0.93) 0.84 (0.79–
0.90)
0.86 (0.82–0.90)
Education (vs. none/primary)
Secondary 0.95 (0.90–1.01) 0.96 (0.89–1.04)
Tertiary 0.84 (0.79–0.89) 0.87 (0.81–0.94)
Employment status
Laborer/service/admin 0.87 (0.82–0.93) 0.96 (0.91–1.02)
Manager/professional 0.78 (0.70–0.86) 0.84 (0.78–0.89)
Marital status (vs. single)
Married 0.86 (0.80–0.93) 0.94 (0.91–0.98) 0.92 (0.87–
0.97)
0.94 (0.90–0.98)
Separated/Divorced 1.01 (0.87–1.16) 0.98 (0.89–1.07) 0.96 (0.86–
1.07)
0.98 (0.89–1.07)
Widowed 0.88 (0.78–0.99) 0.90 (0.84–0.97) 0.95 (0.89–
1.01)
0.96 (0.90–1.02)
HIV risk factor (heterosexual
sex vs. other) 1.00 (0.90–1.11) 1.00 (0.92–1.09)
ART enrollment year
2007–09 vs. 2004–06 0.83 (0.63–1.10) 1.12 (1.03–1.22) 0.93 (0.81–1.06) 1.13 (0.76–1.67) 1.25 (1.06–
1.47)
1.19 (0.99–1.44)
2010–11 vs. 2004–06 0.77 (0.48–1.24) 1.37 (1.13–1.66) 0.94 (0.78–1.13) 1.25 (0.81–1.94) 1.36 (1.10–
1.67)
1.34 (1.06–1.69)
Tertiary Site (vs secondary) 0.72 (0.55–0.95) 0.87 (0.69–1.09)
ART regimen (vs. TDF+FTC/
3TC+EFV)
TDF+FTC/3TC+NVP 1.68 (1.43–1.97) 1.46 (1.26–1.68) 1.57 (1.35–1.83) 1.16 (1.06–1.27) 1.40 (1.23–
1.58)
1.29 (1.15–1.44)
AZT+3TC+EFV 1.34 (1.14–1.59) 1.18 (1.05–1.33) 1.24 (1.12–1.37) 1.00 (0.92–1.10) 0.98 (0.87–
1.09)
0.98 (0.91–1.06)
AZT+3TC+NVP 1.34 (1.13–1.59) 1.30 (1.10–1.54) 1.37 (1.20–1.55) 0.95 (0.83–1.09) 1.12 (1.01–
1.25)
1.07 (0.96–1.18)
D4T+3TC+EFV 1.52 (1.21–1.92) 1.35 (0.96–1.89) 1.17 (0.95–1.43) 0.93 (0.77–1.11) 0.87 (0.69–
1.09)
0.88 (0.71–1.09)
D4T+3TC+NVP 1.68 (1.25–2.27) 1.52 (1.25–1.83) 1.55 (1.37–1.76) 1.12 (0.74–1.69) 1.36 (1.19–
1.56)
1.21 (1.05–1.39)
WHO stage (vs. 1)
2 1.13 (1.01–1.27) 1.03 (0.96–1.10)
3 1.25 (1.09–1.43) 1.10 (0.93–1.30)
4 1.54 (1.32–1.81) 1.14 (0.95–1.36)
TB co-infection 1.00 (0.89–1.11) 0.96 (0.89–1.03)
HBV co-infection 1.10 (1.02–1.18) 1.15 1.07–1.23)
HCV co-infection 0.90 (0.80–1.01) 0.92 (0.82–1.03)
(Continued )
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Table 3. (Continued)
Predictors Virologic Failure Immunologic Failure
Bivariate
Analysis
Complete Multiple
Imputations**
Bivariate
Analysis
Complete Multiple
Imputations**Cases** Cases**
(n = 30,792) (n = 19,454) (n = 30,792) (n = 45,130) (n = 35,836) (n = 45,130)
HR (95% CI) aHR (95% CI) aHR (95% CI) HR (95% CI) aHR (95% CI) aHR (95% CI)
Baseline BMI (vs. normal)
Underweight 1.24 (1.14–1.34) 1.05 (0.95–1.16) 1.03 (0.97–1.09) 1.10 (1.01–1.20)
Overweight 0.90 (0.85–0.96) 1.07 (1.01–1.13) 1.03 (0.98–1.10) 0.93 (0.89–0.98)
Baseline CD4 count, cells/mm3
101–200 vs.100 0.73 (0.67–0.79) 0.82 (0.76–0.89) 0.82 (0.77–0.88) 0.93 0.86–0.99) 0.99 (0.89–
1.12)
1.13 (1.04–1.22)
201–350 vs.100 0.58 (0.53–0.63) 0.71 (0.64–0.78) 0.67 (0.62–0.73) 1.24 (1.13–1.35) 1.43 (1.26–
1.61)
1.68 (1.50–1.89)
>350 vs.100 0.70 (0.57–0.85) 0.78 (0.66–0.93) 0.72 (0.61–0.86) 3.29 (3.01–3.60) 3.56 (3.13–
4.04)
4.39 (3.84–5.03)
Baseline Viral load, copies/mL
10,001−105 vs.104 1.19 (1.12–1.26) 1.06 (0.96–1.17) 1.14 (1.07–1.22) 0.83 (0.80–0.87) 0.89 (0.82–
0.97)
0.96 (0.90–1.03)
>105 vs.104 1.35 (1.22–1.50) 1.16 (1.09–1.23) 1.22 (1.15–1.30) 0.89 (0.84–0.94) 0.93 (0.86–
1.00)
1.00 (0.95–1.06)
Baseline Anemia (vs. no
anemia)
Mild/moderate anemia 1.21 (1.11–1.31) 1.09 (0.94–1.26) 1.07 (1.01–
1.12)
1.04 (1.00–1.09)
Severe anemia 1.35 (1.08–1.68) 1.15 (0.90–1.47) 1.08 (0.99–
1.18)
1.06 (0.99–1.13)
BMI*
Underweight vs. normal 1.18 (0.99–1.40) 1.28 (1.20–1.37) 1.16 (1.07–
1.27)
1.15 (1.06–1.25)
Overweight vs. normal 0.82 (0.71–0.94) 0.85 (0.82–0.88) 0.94 (0.88–
1.00)
0.91 (0.88–0.95)
CD4 count, cells/mm3*
101–200 vs.100 0.37 (0.33–0.40) 0.55 (0.48–0.63) 0.64 (0.56–0.73) 0.72 (0.63–0.82) 0.74 (0.65–
0.84)
0.61 (0.55–0.68)
201–350 vs.100 0.22 (0.19–0.25) 0.47 (0.39–0.57) 0.52 (0.46–0.60) 0.44 (0.36–0.53) 0.44 (0.37–
0.53)
0.37 (0.33–0.41)
>350 vs.100 0.16 (0.13–0.19) 0.44 (0.32–0.59) 0.47 (0.37–0.59) 0.43 (0.35–0.54) 0.40 (0.32–
0.49)
0.27 (0.24–0.31)
Viral load >1000 copies/mL* 77.74 (57.8–
104.5)
68.05 (48.59–
95.31)
38.13 (25.70–56.56) 3.32 (2.75–3.99) 3.20 (2.58–
3.98)
2.11 (1.81–2.45)
Anemia*
Mild/moderate vs. no anemia 1.33 (1.25–1.43) 1.31 (1.13–1.51) 1.28 (1.15–
1.42)
1.24 (1.16–1.32)
Severe vs. no anemia 1.94 (1.72–2.18) 1.90 (1.60–2.24) 1.54 (1.27–
1.88)
1.60 (1.36–1.90)
Avg % adherence (vs.95%)*
80–94.9% 1.50 (1.36–1.67) 1.31 (1.24–1.39) 1.34 (1.20–1.49) 1.19 (1.10–1.29) 1.20 (1.11–
1.30)
1.18 (1.10–1.26)
<80% 3.01 (2.60–3.50) 1.54 (1.43–1.65) 1.81 (1.56–2.11) 2.02 (1.76–2.32) 1.40 (1.23–
1.58)
1.68 (1.47–1.92)
* BMI, CD4 count, viral load, anemia, and average % ART adherence are time-updated covariates except where noted as baseline; all other predictors are
at baseline.
** The final multivariate model is presented, which accounted for correlation within sites using clustered robust standard errors.
doi:10.1371/journal.pone.0164030.t003
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d4T+3TC+NVP patients were at higher risk of VF than those on TDF+FTC/3TC+EFV (aHR:
1.57, 1.24, 1.37, 1.55, respectively).
Similar to VF, the strongest predictors of IF in the adjusted model with multiply imputed
data were lower CD4+ cell count and unsuppressed VL at previous visit, and poorer adherence.
Lower BMI and anemia at previous visit were also predictive of IF. In measuring IF, female sex
was slightly protective as was beingmarried (versus single). Patients on NVP-containing regi-
mens paired with TDF or d4T also appeared to be at a slightly higher risk for IF as compared to
those on TDF+EFV. Unlike what was seen for VF, higher baseline CD4+ cell counts and later
enrollment year were associated with higher risk for IF in both complete case and multiple
imputation adjusted Cox regression models.
Longitudinal Adherence Patterns
We were able to examine long-term adherence patterns for patients that were retained as long
as 84 months post-initiation of ART, with over 5,500 people on ART for over 5 years. We
found that for those that remained in the program or had sufficient years of follow-up time
since enrollment, the majority exhibited very strong (i.e.,95%) adherence for many years
(Fig 8A).
To examine if adherence patterns appear different in patients that were retained long-term
versus those that eventually discontinued treatment, we compared the median percent adher-
ence for each 6-month time interval up to month 36 post-initiation of ART for patients who
were retained on ART versus those that eventually transferred, died, withdrew or were lost to
follow-up. For those that were retained or transferred to another site, the median percent
adherence was above 95% during 0–6 months and rose to 100%. For those that eventually died,
median adherence also started above 95%, but dropped gradually over time on ART and rose
again in those that died closer to 30 months. Finally, for patients that were eventually LTFU or
withdrew, median percent adherence began at 88.5% and never rose above 95% during the
observation period (Fig 8B). We also examined association between initial ART regimen and
adherence and found that patients on d4T-containing regimens had a lower percentage of
patients that retained a95% average adherence over time as compared to those on TDF- or
AZT-containing regimens (Fig 8C).
We also examined the association between baseline CD4+ cell count and early adherence
patterns (i.e., first 6 months on ART). We found that of the patients with baseline CD4+ cell
counts350 cells/mm3, 63.3% had an average adherence of95% during their first 6 months,
where adherence patterns were not significantly different when CD4+ cell count groups were
further stratified into100 cells/mm3, 101–200 cells/mm3, and 201–350 cells/mm3 categories
(63.1%, 62.9%, 64.2%, respectively; Table 2). However, we did find that of patients with base-
line CD4+ cells counts from 351–500 cells/mm3, 56.5% had95% adherence by month 6 and
of those with baseline counts>500 cells/mm3, only 52.5% had95% adherence by month 6.
Additionally, of those with baseline counts of>500, 14.3% had an average adherence of50%
as compared to 11.7% of those with baseline counts from 351–500 cells/mm3 and 6.4% with
counts350 cells/mm3; these differences were statistically significant (p<0.001; Table 2).
Discussion
In this evaluation, we examined long-term outcomes for a large cohort of adult patients
enrolled in the Harvard/APIN PEPFAR program in Nigeria between the years 2004–2012. As a
part of these evaluations, we examined longitudinal patterns in ART regimen prescription pat-
terns, long-term immunologic and virologic outcomes, adherence patterns, and continuous
predictors of treatment failure. Overall, we report strong long-term outcomes, consistent with
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Fig 8. Long-term ART adherence for previously ARV-naïve patients on ART >6 months (N = 49,114). A) All patients on
ART; B) Median percent ART adherence by discontinuation group; and, C) Percent of patients with95% adherence over
time by starting ART regimen.
doi:10.1371/journal.pone.0164030.g008
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data from earlier short- and medium-term evaluations from other international scale-up pro-
grams in South Africa, Ethiopia, Uganda, Botswana, Senegal and China [4,5,7,9,31,32].
In the past decade, the recommended drugs and regimens for optimal ART were changing
worldwide. The patents for many of the early antiretrovirals (ARVs) were expiring and many
generic versions were beingmanufactured in India, Thailand, Brazil, and elsewhere. In addition
to less expensive versions of these drugs, FDCs were made available to reduce the pill burden
and improve adherence. The PEPFAR program provided important assistance in expediting
the U.S. Food and Drug Administration review and approval of these drugs [33]. As a result, by
2008, the cost of drugs for ARVs dropped to levels well below US$300 per year. Despite these
advances, however, the newer and more efficacious drugs being developed in the United States
and Europe remain prohibitively expensive and are still not included in most ART programs in
Africa, leaving the depth of the pharmacy comparatively shallow. As such, this evaluation of
outcomes focuses on a limited set of 1L regimens. Our data indicated that during the early
years of enrollment, the majority of patients were on d4T-containing 1L regimens. Over the
years, d4T was phased out, with AZT-containing regimens slowly predominating and a gradual
increasing percentage of patients being initiated on TDF-containing regimens.
Despite the low variety in types of ARVs, as the general availability of ART rapidly increased
with scale-up of PEPFAR and Global Fund supported programs and theWHO recommenda-
tions for initiating ART evolved over these years, increasing CD4 count criteria from 200 to
350 cells/mm3, we hypothesized that the baseline clinical characteristics of newly enrolled
patients changed over the enrollment years. As expected, this study revealed higher baseline
CD4+ cell counts and greater proportion of patients enrolling at lower WHO stages in the pro-
gram from 2004–2012. As the years passed, and the sicker patients enrolled on ART during the
early years of the program, the patients enrolled in later years typically were initiated at higher
baseline CD4+ cell counts. Of note, in 2013, the WHO recommended that ART should be initi-
ated in all individuals with a CD4 count>350 and500 cells/mm3. Additional evaluations on
data beyond 2013 would be expected to reveal even higher median CD4+ cell counts.
While the enrolled patient population started with relatively low median CD4+ cell counts
at ART initiation, the rate of immune recovery was strong up through 84 months of follow-up.
Viral suppression rates were also high out to 84 months of follow-up, mimicking the findings
from some recent, smaller middle- and long-term outcome analyses conducted in Botswana,
South Africa, Senegal, and Uganda [4,31,32,34].
A study by Lima et al., from British Columbian, Canada, indicated that patients that started
ART with CD4+ cell counts of at least 500 cells/mm3 were more likely to be virally suppressed
at 9 months post-initiation that than those with lower starting CD4+ cell counts [11]. In our
evaluation, we found that patients that initiated ART with baseline CD4+ cell counts between
201–350 cells/mm3 were more likely than those with lower and higher baseline CD4+ cell
counts to be suppressed at both month 6 and month 12 post-initiation of ART. From a clinical
perspective, it makes sense that patients starting with the lower CD4+ cell counts would need
more time to achieve viral suppression. However, for the groups starting with higher CD4+ cell
counts, it is possible that they were feeling well at the time they startedmedication and per-
ceived a lower benefit to taking all of their medications or maintaining a high level of adher-
ence. Interestingly, we also found that early average adherence was lower for those with
baseline CD4+ cell counts>350 cells/mm3 as compared to those patients with counts350
cells/mm3. Furthermore, we found a higher relative hazard of virologic failure for patients with
baseline CD4>350 cells/mm3 compared with those with baseline CD4 of 201–350 cells/mm3.
This finding is consistent with those of Grimsrud et al, who found that patients with baseline
CD4 counts300 cells/μL were more likely to be LTFU after 24 months on ART than those
patients with CD4 counts of 150–199 μL [35]. Additional studies should be conducted to better
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understand the associations between higher baseline CD4+ cell counts and subsequent viral
suppression rates, particularly as countries are moving towards large-scale roll-out of test and
treat programs.
The regular measurement of VLs was a unique feature of our program, allowing for assess-
ment of VF, the most objective determination of ART outcome as would be measured in
resource-rich settings. The baseline risk factors for VF we found (younger age, lower CD4
count, and higher VL) and the time-updated risk factors (lower CD4 count, unsuppressed VL,
and poorer adherence) should be useful in identifying higher risk patients for targeted adher-
ence counseling and monitoring strategies.While one recent study of long-term outcomes in
Cameroon showed increased risk for VF in males versus females [6], in our analyses of over
30,000 patients, we were not able to corroborate the finding similar to another recent study
from Uganda [7]. The increased risk for VF for patients on NVP regimens compared to EFV
regimens for all three NRTIs suggests that NVP regimens should be prescribed cautiously
when appropriate. Scarsi et. al. showed that patients who initiated ART on TDF in combina-
tion with NVP had higher risk of VF than patients who initiated on AZT with NVP in our pro-
gram [36], which our data also show. Additionally, our data indicate that patients who initiated
on TDF in combination with EFV had lower risk for VF than those on AZT with EFV, which
has previously been shown in a randomized clinical trial [37]. Our findings support the view
that NNRTI effectiveness differs by NRTI selection, possibly due to drug-drug interactions
[36], and are consistent with theWHO recommendations that EFV is used as the preferred
NNRTI in a patient newly initiated ART [38].
Interestingly, unlike for VF, higher baseline CD4+ cell counts were associated with IF; this
may be because those with higher baseline CD4+ cell counts are more likely to have their CD4
+ cell count drop below baseline, one of the criteria for immunologic failure, during ART than
those with already low baseline levels. This may also explain why later enrollment year was also
weakly associated with higher risk of immunologic failure as the baseline CD4+ cell count cri-
teria for ART enrollment increased in 2010.
Just as our previous evaluation showed that the largest percentage of patient LTFU occurred
during the first 12–18 months of ART [39], we found that risk of virologic failure was also
highest in the first year on ART and decreasedwith longer duration on ART. Thus, the first
year of ART, and particularly the first few visits, is a crucial time for adherence counseling and
monitoring adherence directed interventions [5,39]. ART knowledge among patients and
health care workers, drug adherence counseling, and patient monitoring are crucial for optimi-
zation of patient outcomes.
Because we had both VF and IF data, we were able to examine accuracy of IF criteria to pre-
dict VF in a large cohort of patients. Similar to the earlier study by Rawizza et al. [40], but now
in a larger cohort with additional years of data, we can re-confirm that IF criteria is not a strong
predictor of VF and that VF criteria detect failure almost 5 months earlier than IF criteria.
These findings are important to consider in making decisions about treatment switch and have
implications when considering development of drug resistance mutations with each additional
month on a failing drug regimen.
Our study also demonstrated strong long-term adherence, similar to what was found in a
smaller, middle-termART cohort study from Botswana [31], further indicating that sustained,
long-term positive outcomes are possible in sub-Saharan African settings. Interestingly, we
found an association between higher baseline CD4+ cell counts and decreased adherence; it
might be speculated that patients that felt healthier might be less likely to adhere. These data
are consistent with the associations previously noted between adherence and viral suppression
as well as adherence and immunologic failure.
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This evaluation does have some limitations. As a retrospective observational cohort study,
this analysis was limited by missing data, which was expected considering the rapid scale-up of
the program and data collection in the context of routine care. While we attempted to control
for some of the missing data issues through use of multiple imputation methods, it is possible
that patients who were missing certain time-updated clinical laboratory values may have been
more likely to develop failure than those who were not missing data, which may have affected
the imputation results and the magnitudes of association in the multivariate models. The study
was limited because the program did not actively trace all patients that were lost, which likely
resulted in an overestimation of LTFU and underestimation of mortality, transfers and with-
drawals as has been indicated in previous other studies in which LTFU patients were traced
[41–47]. The VF analysis only included patients who were retained on ART and for whom we
could evaluate VF using the program definition and does not include those with fewer than
two VLs; thus, our failure rates do not include patients who were lost to follow-up or who had
fewer than two VLs, which are in themselves problematic outcomes for large-scale ART pro-
grams. Also, we censored failure patients at their first failing VL or switch to 2L ART, and did
not assess substitutions to other 1L ART regimens or second failures, which could provide use-
ful insight. Finally, as this was an observational cohort study, we were not able to control for all
factors related to virologic failure and there is residual confounding that must be considered in
interpretation of the regimen comparison data.
This evaluation also has notable strengths. The large enrollment of the program and lengthy
follow-up provide statistical strength to reinforce our findings. To our knowledge, other large
cohorts examining ART outcomes include one from Botswana, which describedmedium-term
outcomes for over 126,000 patients [48] and another multi-cohort study that presented
medium-term retention data for over 130,000 patients across Africa and Asia [3]. Additionally,
a recent meta-analysis consolidate information on multiple short-, medium- and long-term
analyses, but none with over 70,000 patients, where at least 5,500 have over 5-years of ART out-
come data [49]. Furthermore, our continual 6-month measurements for critical variables
enabled us to correlate VF with these risk factors as they changed over time. Unlike other eval-
uations of long-term clinical outcomes, this analysis included time-updated clinical and adher-
ence data, which we found to be better predictors of treatment failure, whethermeasured by
virologic or immunologic criteria, than the baselinemeasurements alone.
Conclusion
The United Nations Sustainable Development Goals (SDGs) aims to see an end to the HIV/
AIDS epidemic by 2030. While access to ART rose dramatically between 2004 to 2014 as a
result of major contributions from the massive scale-up programs supported by PEPFAR, the
Global Fund for Tuberculosis, AIDS and Malaria, theWorld Bank, the Clinton Foundation, it
was estimated in 2013 that only 20% of patients in Nigeria that required ART were actually
receiving it [1]. Clearly, much remains to be done if the SDGs are to be achieved in Nigeria by
2030. The progress thus far and positive long-term outcomes for patients that initiated ART
suggest, however, that these ambitious goals are achievable.
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